Use of Glycolysis-Enhancing Drugs and Risk of Parkinson's Disease.

ABSTRACT:

Background

Terazosin (TZ) and closely related α1-adrenergic receptor antagonists (doxazosin [DZ] and alfuzosin [AZ]) enhance glycolysis and reduce neurodegeneration in animal models. Observational evidence in humans from several databases supports this finding; however, a recent study has suggested that tamsulosin, the comparator medication, increases the risk of Parkinson's disease.

Aims

We consider a different comparison group of men taking 5α-reductase inhibitors (5ARIs) as a new, independent comparison allowing us to both obtain new estimates of the association between TZ/DZ/AZ and Parkinson's disease outcomes and validate tamsulosin as an active comparator.

Methods

Using the Truven Health Analytics Marketscan database, we identified men without Parkinson's diseas

SUBMITTER: Simmering JE 

PROVIDER: S-EPMC9669185 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature